Literature DB >> 25816088

Stereotactic radiosurgery for intracranial hemangioblastomas: a retrospective international outcome study.

Hideyuki Kano1, Takashi Shuto2, Yoshiyasu Iwai3, Jason Sheehan4, Masaaki Yamamoto5, Heyoung L McBride6, Mitsuya Sato7, Toru Serizawa8, Shoji Yomo9, Akihito Moriki10, Yukihiko Kohda11, Byron Young12, Satoshi Suzuki13, Hiroyuki Kenai14, Christopher Duma15, Yasuhiro Kikuchi16, David Mathieu17, Atsuya Akabane18, Osamu Nagano19, Douglas Kondziolka20, L Dade Lunsford1.   

Abstract

OBJECT: The purpose of this study was to evaluate the role of stereotactic radiosurgery (SRS) in the management of intracranial hemangioblastomas.
METHODS: Six participating centers of the North American Gamma Knife Consortium and 13 Japanese Gamma Knife centers identified 186 patients with 517 hemangioblastomas who underwent SRS. Eighty patients had 335 hemangioblastomas associated with von Hippel-Lindau disease (VHL) and 106 patients had 182 sporadic hemangioblastomas. The median target volume was 0.2 cm(3) (median diameter 7 mm) in patients with VHL and 0.7 cm(3) (median diameter 11 mm) in those with sporadic hemangioblastoma. The median margin dose was 18 Gy in VHL patients and 15 Gy in those with sporadic hemangioblastomas.
RESULTS: At a median of 5 years (range 0.5-18 years) after treatment, 20 patients had died of intracranial disease progression and 9 patients had died of other causes. The overall survival after SRS was 94% at 3 years, 90% at 5 years, and 74% at 10 years. Factors associated with longer survival included younger age, absence of neurological symptoms, fewer tumors, and higher Karnofsky Performance Status. Thirty-three (41%) of the 80 patients with VHL developed new tumors and 17 (16%) of the106 patients with sporadic hemangioblastoma had recurrences of residual tumor from the original tumor. The 5-year rate of developing a new tumor was 43% for VHL patients, and the 5-year rate of developing a recurrence of residual tumor from the original tumor was 24% for sporadic hemangioblastoma patients. Factors associated with a reduced risk of developing a new tumor or recurrences of residual tumor from the original tumor included younger age, fewer tumors, and sporadic rather than VHL-associated hemangioblastomas. The local tumor control rate for treated tumors was 92% at 3 years, 89% at 5 years, and 79% at 10 years. Factors associated with an improved local tumor control rate included VHL-associated hemangioblastoma, solid tumor, smaller tumor volume, and higher margin dose. Thirteen patients (7%) developed adverse radiation effects (ARE) after SRS, and one of these patients died due to ARE.
CONCLUSIONS: When either sporadic or VHL-associated tumors were observed to grow on serial imaging studies, SRS provided tumor control in 79%-92% of tumors.

Entities:  

Keywords:  ARE = adverse radiation effects; Gamma Knife; KPS = Karnofsky Performance Status; NAGKC = North American Gamma Knife Consortium; SRS = stereotactic radiosurgery; UPMC = University of Pittsburgh Medical Center; UVA = University of Virginia; VHL = von Hippel–Lindau disease; hemangioblastoma; stereotactic radiosurgery; von Hippel–Lindau disease

Mesh:

Year:  2015        PMID: 25816088     DOI: 10.3171/2014.10.JNS131602

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  15 in total

Review 1.  Updates in the management of intradural spinal cord tumors: a radiation oncology focus.

Authors:  Rupesh Kotecha; Minesh P Mehta; Eric L Chang; Paul D Brown; John H Suh; Simon S Lo; Sunit Das; Haider H Samawi; Julia Keith; James Perry; Arjun Sahgal
Journal:  Neuro Oncol       Date:  2019-06-10       Impact factor: 12.300

2.  Stereotactic radiosurgery for central nervous system hemangioblastoma: systematic review and meta-analysis.

Authors:  James Pan; Rashad Jabarkheel; Yuhao Huang; Allen Ho; Steven D Chang
Journal:  J Neurooncol       Date:  2017-12-04       Impact factor: 4.130

3.  Growth rate and fate of untreated hemangioblastomas: clinical assessment of the experience of a single institution.

Authors:  Joonho Byun; Hee Jun Yoo; Jeong Hoon Kim; Young Hoon Kim; Young Hyun Cho; Seok Ho Hong; Chang Jin Kim
Journal:  J Neurooncol       Date:  2019-06-14       Impact factor: 4.130

4.  Gamma Knife Stereotactic Radiosurgery favorably changes the clinical course of hemangioblastoma growth in von Hippel-Lindau and sporadic patients.

Authors:  Brittany Liebenow; Abigail Tatter; William A Dezarn; Scott Isom; Michael D Chan; Stephen B Tatter
Journal:  J Neurooncol       Date:  2019-02-07       Impact factor: 4.130

Review 5.  Central Nervous System Hemangioblastoma in a Pediatric Patient Associated With Von Hippel-Lindau Disease: A Case Report and Literature Review.

Authors:  Bo Yang; Zhenyu Li; Yubo Wang; Chaoling Zhang; Zhen Zhang; Xianfeng Zhang
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

6.  [Hemangioblastomas of the posterior fossa: Report of 16 cases and literature review].

Authors:  Alvaro Campero; Pablo Ajler; Julio Fernandez; Gustavo Isolan; Martin Paiz; Conrado Rivadeneira
Journal:  Surg Neurol Int       Date:  2016-11-21

7.  Differential diagnosis of posterior fossa brain tumors: Multiple discriminant analysis of Tl-SPECT and FDG-PET.

Authors:  Moritaka Yamauchi; Tomohisa Okada; Tsutomu Okada; Akira Yamamoto; Yasutaka Fushimi; Yoshiki Arakawa; Susumu Miyamoto; Kaori Togashi
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

8.  VHL-Associated Optic Nerve Hemangioblastoma Treated with Stereotactic Radiosurgery.

Authors:  Hiroshi Kanno; Seiki Osano; Masamichi Shinonaga
Journal:  J Kidney Cancer VHL       Date:  2018-06-06

Review 9.  Management Strategies and Outcomes for VHL-related Craniospinal Hemangioblastomas.

Authors:  Christ Ordookhanian; Paul E Kaloostian; Samer S Ghostine; Philippe E Spiess; Arnold B Etame
Journal:  J Kidney Cancer VHL       Date:  2017-08-28

10.  Assessment of care pattern and outcome in hemangioblastoma.

Authors:  Yuqian Huang; Lilian Chan; Harrison X Bai; Xuejun Li; Zishu Zhang; Yinyan Wang; Ya Cao; Giorgos Karakousis; Raymond Huang; Bo Xiao; Paul J Zhang; Li Yang
Journal:  Sci Rep       Date:  2018-07-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.